Zealand Pharma is the more experienced player In that vein, Viking Therapeutics (VKTX -7.17%) and Zealand Pharma (ZLDP.F -2.44%) are among the best biotechs aiming to enter the cardio-metabolic space in the next few years. Here's how they shape up in a headto-head comparison. That implies that Viking might not need to manufacture as much of its candidate to meet demand, which is an advantage. Furthermore, the side-effect profile is similar to the reigning champions, but, importantly, patients can in theory ...

One preliminary piece of evidence is sending its shares higher. Viking Therapeutics (VKTX 2.01%) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the bull thesis for its continued outperformance is stronger than ever. It's clear now that the biotech has what it'll need to take on powerful competitors like Eli Lilly and Novo Nordisk. Here's why. Strong clinical data and minimal expenditures make a v ...

All of this has pushed shares of Viking to major gains this year, with performance even surpassing that of AI powerhouse Nvidia. Viking is developing injectable and oral GIP and GLP-1 receptor agonists, treatments that act on hormones controlling blood sugar levels and appetite. Just last week, the company said it's advancing VK-2735, its injectable candidate, into a phase 3 trial and has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration for later this year. In the phase 2 trial ...

Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new classes of effective treatments is just getting started. According to a forecast by Goldman Sachs Research, the global weight loss drug market may multiply by a factor of 16 to reach $100 billion by the end of the decade. Unlike Eli Lilly and Novo Nordisk, Viking is a clinical-stage company. It doesn't have any p ...

Viking Therapeutics Today VKTX Viking Therapeutics $69.04 +18.63 (+36.96%) 52-Week Range $8.28 ▼ $99.41 Price Target $111.56 Add to Watchlist Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community. Following the release of its ear ...

The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product. This weight loss was better than the amount achieved by Eli Lilly's Zepbound and Novo Nordisk's Wegovy in clinical trials. With VK2735 advancing into late-stage testing, investors know that Viking will be closer to potentially launching what could be a blockbuster drug. Risk-averse investors should probably stay on the sidelines with Viking. However, I think the biotech stock is a great pick for ag ...

It brings the San Diego-based company one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. Shares of both Novo Nordisk and Eli Lilly fell around 2% in premarket trading Thursday. But after receiving written feedback from the Food and Drug Administration, the company has decided to move the injection directly into a phase three trial, CEO Brian Lian said during an earnings call on Wednesday. That decision will like ...

The results from the Phase 2 trial showed much promise with it meeting its primary and all secondary endpoints. That includes significant weight loss for those taking VK2735 when compared to patients taking a placebo. To go along with this, the company reported adjusted EPS of -20 cents in the second quarter of 2024. That's worth highlighting as it beats out Wall Street's estimate of -24 cents for the quarter. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical t ...

Stephanie Diaz I'll now turn the call over to Brian Lian for his initial comment. I'll summarize the highlights from these studies later in the call. During the second quarter, Viking also announced early results from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. These compounds demonstrated body weight reductions, decreased food intake, and improved metabolic profile in animal models. Stephanie Dia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...